4. HYMOVIS® [package insert]. Fidia Farmaceutici S.P.A. Abano Terme, Italy 2017. 5. Bisicchia S, Bernardi G, Tudisco C. HYMOVIS® (HYADD® 4) versus methylprednisolone acetate in symptomatic knee osteoarthritis: a single-centre single blind prospective randomised controlled clinical stud...
A BREAKTHROUGH in the treatment of osteoarthritis (OA) knee pain, HYMOVIS® is helping active people everywhere write their own story about moving past pain and back to the things they love in life. If a simple, two-injection regimen for convenient and
506 HYMOVIS™, A HEXADECYLAMIDE HYALURONAN DERIVATIVE (HYADD®4-G), INHIBITS GENE EXPRESSION CHANGES INDUCED BY INTERLEUKIN-lp IN CHONDROCYTES AND SYNOVIAL FIBROBLASTS DERIVED FROM OSTEOARTHRHIS PATIENTS - ResearchGatedoi:10.1016/S1063-4584(11)60533-5M. M. Smith...
A novel slightly modified hyaluronic acid, HYADD4 (Hymovis;), has recently been tested in an ovine meniscectomy model of osteoarthritis, causing a reduction of vascularity and intimal hyperplasia, and an increase in the synthesis of high molecular weight HA by synovial fibroblasts (1). HYADD4 ...